Search Results
Your search for The A,The A matches 32372 pages
Showing 11701 - 11750FDA Approves Ripretinib for Previously Treated Patients With Advanced Gastrointestinal Stromal Tumor
On May 15, the U.S. Food and Drug Administration (FDA) approved ripretinib (Qinlock) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. INVICTUS Trial Efficacy was...
FDA Approves Nivolumab/Ipilimumab for First-Line Treatment of Patients With Metastatic NSCLC and PD-L1 Tumor Expression ≥ 1%
On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express programmed cell death ligand 1 (PD-L1) at ≥ 1%, as...
Selected Poster Presentations on Cancer Therapeutics and More
Although the live 2020 National Comprehensive Cancer Network (NCCN) Annual Conference was canceled, more than 100 posters scheduled for presentation are now available online, as part of the NCCN 2020 Virtual Annual Conference. The ASCO Post has summarized some of the clinical trial updates we found ...
10 Changes I Will Make in My Oncology Practice as a Result of COVID-19
As a result of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or COVID-19) global pandemic, medicine—including oncology practice—will never be the same. We find ourselves in a time of emergency medicine for all specialties, technologic innovation (eg, more prevalent use of...
Study Finds a High Rate of Intra- and Postoperative Conversions to Total Thyroidectomy
The overall risk of needing a total thyroidectomy was found to be 19.4% for patients undergoing lobectomy for indeterminate and high-risk thyroid nodule, according to a report published by Moore et al in the World Journal of Surgery. The study also found that 21% and 26.5% of patients originally...
FDA Approves Pomalidomide for Kaposi Sarcoma
On May 14, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of pomalidomide (Pomalyst) to include treating adult patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failure of highly active antiretroviral therapy and those with Kaposi...
Does Text Messaging Support Adherence to Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer?
In the SWOG S1105 trial reported in the Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, and colleagues found that a text message intervention did not reduce the rate of early discontinuation of adjuvant aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer....
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
New Study Shows Patients With Cancer Had Lower Rates of Detected COVID-19 Antibodies vs Health-Care Workers
Results from an analysis involving both patients with cancer and health-care workers at Centre Léon Bérard in Lyon, France, showed that patients with cancer had a significantly lower detection rate of SARS-CoV-2 antibodies 15 days or more after COVID-19 symptoms and a positive reverse transcription ...
Combining Pembrolizumab With IL-12 Electroporation May Improve Clinical Response in Patients With Immunologically 'Cold' Melanoma
Patients with non–immune-infiltrated “cold” tumors have low frequencies of intratumoral tumor-reactive, checkpoint-positive cytotoxic lymphocytes, making them less responsive to checkpoint blockage than patients with immune-infiltrated “hot” tumors. A phase II study by Alain P. Algazi, MD, and...
First-Line Concomitant and Sequential Nivolumab/AVD for Early-Stage Unfavorable Classical Hodgkin Lymphoma
In a phase II German Hodgkin Study Group trial (NIVAHL) reported in JAMA Oncology, Bröckelmann et al found that both concomitant and sequential nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) regimens showed efficacy in first-line treatment of early-stage unfavorable classical...
Effectiveness of Different Severity Thresholds for Chemotherapy-Related Symptom Alerts
In a study reported in JCO Oncology Practice, Shi et al found that use of higher-than-currently-recommended severity thresholds for symptom alerts for patients receiving outpatient chemotherapy would result in failure to identify and treat many patients requiring clinical intervention for ...
Quitting Smoking at Any Point Improves Lung Cancer Survival, Study Finds
People who quit smoking at any time—even 2 years before a lung cancer diagnosis—improve their chances of survival after being diagnosed with the disease, according to the results of a large international study presented by Fares et al in a press briefing in advance of the ASCO20 Virtual Scientific...
Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib
Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced non–small cell lung cancer and brain metastases. The trial suggested capmatinib showed antitumor activity in the brain, regardless of...
Nickolas Papadopoulos, PhD, on Liquid Biopsy to Screen for Multiple Cancer Types
Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women with no history of cancer. The test, called DETECT-A, identified 10 different cancer types, 65% of which were early-stage...
Videoconference Intervention Can Reduce Levels of Anxiety and Distress Among Distance Caregivers
According to the National Alliance for Caregiving, the number of adult individuals in the United States providing care for patients with cancer ranges between 2.8 million and 6.1 million. Caregivers for patients with cancer who live more than 1 hour away report having higher levels of anxiety and...
Expert Point of View: William Dale, MD, PhD
"We have known for a long time, based on good evidence, that geriatric assessment is good at accurately identifying patients at high risk for chemotherapy-induced toxicity, surgical complications, and increased hospitalizations. This study adds an intervention component based on the geriatric...
Geriatrician Assessment and Integrated Care May Help Older Patients as Well as the Health-Care System
A full geriatric assessment and geriatrician-led multidisciplinary care improved the quality of life of patients aged 70 and older undergoing chemotherapy, targeted therapy, or immunotherapy, according to results of a prospective, randomized, controlled, open-label trial, reported in a press...
Expert Point of View: Don S. Dizon, MD, FACP, FASCO
Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer
For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...
Study Finds Cancer-Related Deaths Declined in States With Expanded Access to Medicaid
States that adopted Medicaid expansion after passage of the Affordable Care Act (ACA) in 2010 saw a decline in cancer mortality rates by 29% compared with 25% in states that did not expand access to Medicaid, according to a study by Anna Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, New...
Cancer vs COVID-19: Clinical Trial Research During the Pandemic
The COVID-19 pandemic transformed cancer care, seemingly overnight, as practices scrambled to ensure a safe environment for caregivers and patients. Although regulatory burdens have been relaxed to allow patients to continue on trial treatment and telemedicine has expanded its competency and reach, ...
How the Lung Cancer Community Came Together During the COVID-19 Pandemic
The COVID-19 pandemic (caused by infection with the SARS-CoV-2 coronavirus) has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and providers. Everyone wanted to...
Spartalizumab for Locally Advanced or Metastatic Anaplastic Thyroid Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Jaume Capdevila, MD, and colleagues found that the programmed cell death protein 1 (PD-1) inhibitor spartalizumab produced responses in a cohort of patients with locally advanced or metastatic anaplastic thyroid carcinoma, with all...
Highlights From the AACR Virtual Annual Meeting
This week, we’ll be featuring some research highlights from the AACR Virtual Annual Meeting, including data on a triplet regimen for women with high-risk, HER2-negative breast cancer; findings on immunotherapy combined with targeted therapy for patients with BRAF V600-mutated melanoma; and a paper...
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
Expert Point of View: Charles L. Sawyers, MD
Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, New York, commented on the SWOG S1320 study presented at the 2020 American Association for Cancer Research Virtual Annual Meeting. “Intermittent therapy is standard with chemotherapy due to toxicity, but targeted therapies...
AACR 2020: Continuous Dosing of Dabrafenib Plus Trametinib Improves Progression-Free Survival vs Intermittent Dosing in Advanced Melanoma
Continuous dosing with dabrafenib and trametinib improved progression-free survival in patients with BRAF-mutated advanced melanoma compared with an intermittent-dosing strategy, according to results of the phase II SWOG S1320 randomized trial reported at the opening Plenary Session of the 2020...
Don’t Touch Me With a 6-Foot Pole
The universe has an intriguing way of registering our wishes and delivering them in convoluted, mutated forms. Last winter, I recall coming home after a long day at the hospital and being ambushed by my 3-year-old daughter and preteen son. She wanted to play, he needed help with homework, and they ...
Can Communication Skills Training for Oncologists Improve Discussion of Goals of Care for Patients With Advanced Cancer?
In a study reported in JCO Oncology Practice, Bickell et al found that providing oncologists with communication skills training did not improve the frequency or quality of goals-of-care discussions for patients with advanced cancer. Study Details In the study, 22 oncologists were randomly assigned...
Ruxolitinib in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Stem Cell Transplant
In the phase III REACH2 trial reported in The New England Journal of Medicine, Zeiser et al found that the JAK1/2 inhibitor ruxolitinib improved response rate vs investigator’s choice of therapy in patients with glucocorticoid-refractory acute graft-vs-host disease (GVHD) following allogeneic stem...
Can a Culturally Tailored Education Program Improve Colorectal Cancer Awareness and Screening?
People who received information from the Screen to Save program, a culturally tailored initiative from the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities (CRCHD), increased their knowledge of colorectal cancer and indicated willingness to adopt potentially preventive...
Half of Surveyed Cancer Researchers Report Their Work Is on Hold Due to the COVID-19 Pandemic
A survey of American Cancer Society grantees found that about half reported their cancer research has been halted as a result of the COVID-19 pandemic. The American Cancer Society reached out to all of its funded researchers to assess the state of their projects and collect information to guide...
FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo) for the following indications: Adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or...
In ‘Remembering Mum,’ Siblings Honor Their Mother With Action and Innovation
It’s one of the worst things Claire Paxman can recall: She’s 14 years old, using orange-handled kitchen scissors to cut her mother’s hair. “You shouldn’t be standing in the bathroom cutting your mom’s hair because of chemotherapy,” said Claire as she describes that defining childhood moment when ...
Financial Support Available to Providers During COVID-19 Pandemic
The Coronavirus Aid, Relief, and Economic Security (CARES) Act and new guidance from the Centers for Medicare & Medicaid Services (CMS) both contain provisions to provide financial support to qualified providers. ASCO strongly encourages providers to immediately begin meticulously documenting...
ASCO’s COVID-19 Cancer Registry Aims to Understand Impact on Patients During Pandemic, Inform Future Care
ASCO has launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes. ...
Scott Kopetz, MD, PhD, FACP: Breakthroughs in Combination Therapy for Colorectal Cancer
Scott Kopetz, MD, PhD, FACP, works to improve outcomes for patients with colorectal cancer at The University of Texas MD Anderson Cancer Center. The trial: Single drugs aimed at inhibiting the BRAF gene have not been effective against BRAF-mutated colorectal cancers. To explore the effectiveness...
My ASCO Journey: Opportunities for Gratitude and Breaking Glass Ceilings
In my native language, there is a saying that is translated as, “A child who does not travel only appreciates their mother’s cooking.” In the broad sense, as we grow up and experience the different things that life has to offer, two things happen if we allow our minds to open up: we realize there...
Ongoing Efforts Toward Vaccine Development for COVID-19
Coronavirus disease 2019 (COVID-19) is spreading throughout the world, and vaccine developers have responded with unprecedented speed. Since the COVID-19 genome sequence was released in January, human trials of an experimental vaccine candidate have already begun in the Seattle area. Although the...
I Have Multiple Myeloma and Am Concerned About the Coronavirus
In hindsight, the symptoms I began experiencing in the fall of 2013—sudden excruciating back bone pain and severe fatigue—should have tipped me off that I had a serious disease, but 7 years ago, they were easy to explain away. The bone pain was similar to what I had experienced several years...
Yoga for Pediatric and Adolescent Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Despite significant improvements reported in survival rates, symptom management in pediatric...
Global COVID-19 Observatory and Resource Center for Childhood Cancer
St. Jude Children’s Research Hospital, in partnership with the International Society of Paediatric Oncology (SIOP), has launched the Global COVID-19 Observatory and Resource Center for Childhood Cancer. The website offers health-care providers around the world a space to share the latest...
Breast Surgeon Kristin L. Brill, MD, Joins Sidney Kimmel Cancer Center
Kristin L. Brill, MD, has joined the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) in Philadelphia as Enterprise Director of Breast Oncology. Dr. Brill brings expertise in a comprehensive range of services for patients with malignant and benign diseases, including breast-conserving surgery,...
Aria Vaishnavi, PhD, Receives NCI’s Pathway to Independence Award
Aria Vaishnavi, PhD, a postdoctoral fellow at the Huntsman Cancer Institute at the University of Utah, has received the first annual National Cancer Institute (NCI) Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00). The “Early K99” grant supports...
Fox Chase Cancer Center Welcomes Andres F. Correa, MD
Fox Chase Cancer Center announced that Andres F. Correa, MD, has joined the Department of Surgery in the Urologic Oncology Division as Assistant Professor. Dr. Correa, w ho was a Society of Urologic Oncology Fellow at Fox Chase, is returning to the center after serving as Attending Surgeon and...
Parker Institute for Cancer Immunotherapy Appoints Frederic Pla, PhD, as Chief Operating Officer
The Parker Institute for Cancer Immunotherapy (PICI) recently announced the appointment of Frederic Pla, PhD, as its Chief Operating Officer (COO). Dr. Pla will lead day-to-day operations and work with the Institute’s leadership team to establish goals for performance, expansion, and sustainable...
Durvalumab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer
On March 27, 2020, durvalumab (Imfinzi) was approved for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer.1,2 Supporting Efficacy Data Approval was based on the findings of the open-label phase III ...
Grace and Forgiveness
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Encorafenib Combined With Cetuximab in Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer
On April 8, 2020, encorafenib was approved for use in combination with cetuximab for the treatment of previously treated adult patients with metastatic colorectal cancer with a BRAF V600E mutation detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 Encorafenib is not indicated...
